Cartesian Therapeutics, Inc.

NASDAQ:RNAC

Biotechnology

Healthcare
$6.30 -4.15%

-$0.41 today

Market cap
$192.17M
Beta
0.78
P/E (TTM)
-1.7
EPS (TTM)
-$5.65
52W Low $5.60High $15.57

Volume 0.17M

Average 0.26M

RNAC Operating Margin

Operating income as a percentage of revenue, showing the profitability of core operations.

Cartesian Therapeutics, Inc.NASDAQ: RNAC

Operating Margin · Q1 FY2026 · quarter ended Mar 2026

Operating margin narrows to -33973.1%

Operating margin was -33973.1% in Q1 FY2026, down 31983.2 pp from a year earlier. On a trailing-twelve-month basis it was -5144.5%, down 4991.1 pp year over year. Over 3 fiscal years it narrowed by 3113.1 pp.

Context

  • Operating margin widened in 1 of the last 3 fiscal years.
  • FY2025 was the lowest level in the 4 fiscal years shown.

What to watch

Whether operating margin reaches the consensus estimate from 5 analysts of -13682.4% for the fiscal year ending Dec 2026, down from -3099.9% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-33973.1%-31656.4 pp QoQ
Last fiscal yearDec 2025
-3099.9%-2987.1 pp YoY
LTMMar 2026
-5144.5%-4991.1 pp YoY
Operating Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-31983.2 pp-7015.7 pp+24967.4 pp
1 year-2987.1 pp-10582.4 pp-7595.3 pp
3 years-3113.1 pp+2682.4 pp+5795.5 pp
5 years+3083.4 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Operating Margin history

Percent of revenue · from the income statement

Latest · FY2025
-3099.9%
Year-over-year change
-2987.1pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Operating Margin vs competitors

How RNAC compares with its peers on the latest reported figures

  • RNAC's LTM Mar 2026 operating margin of -5144.5% is the 5th highest of the 7 companies compared; the peer median is -1557.3%.
  • Its year-over-year change of -4991.1 pp is the 5th highest of 6, against a peer median of -85.0 pp.
  • Over three fiscal years its change of -3113.1 pp compares with a peer median of -120.1 pp.
RNAC Competitors Peer median
Operating Margin for RNAC and competitors
Company Period LTM level YoY 3-year change
FENCFennec Pharmaceuticals Inc.LTM Mar 2026-11.0% +27.9 pp+1467.1 pp
OBIOOrchestra BioMed Holdings, Inc.LTM Mar 2026-168.0% +2215.9 pp+769.6 pp
MDWDMediWound Ltd.LTM Mar 2026-193.6% -85.0 pp-120.1 pp
IVAInventiva S.A.FY2025-2921.0% -1860.3 pp-2452.0 pp
RNACCartesian Therapeutics, Inc.LTM Mar 2026-5144.5% -4991.1 pp-3113.1 pp
AVTXAvalo Therapeutics, Inc.LTM Mar 2026-134164.4% -122732.2 pp-123394.3 pp
NTHINeonc Technologies Holdings, Inc.FY2025-145459.4% ——
EPRXEupraxia Pharmaceuticals Inc.FY2025— ——
NAUTNautilus Biotechnology, Inc.FY2025— ——
AARDAardvark Therapeutics, Inc. Common StockFY2025— ——
Peer median (excluding RNAC) -1557.3%-85.0 pp-120.1 pp

Competitors are the stored peer set for RNAC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue85.08M110.78M26M38.91M2.8M
Cost of Revenue02.04M000
Gross Profit85.08M108.74M26M38.91M2.8M
Gross Margin100.0%98.2%100.0%100.0%100.0%
Research & Development68.74M72.38M71.26M45.11M58.03M
Selling, General & Admin20.94M23.86M40.45M30.13M31.47M
Operating Expenses89.67M94.2M112.42M82.81M89.5M
Depreciation & Amortization1.72M2.04M843K1.15M2.96M
EBITDA(5.16M)39.84M(235.03M)(75.99M)(136.54M)
EBITDA Margin-6.1%36.0%-903.8%-195.3%-4881.5%
Operating Income(4.6M)14.54M(86.42M)(43.9M)(86.71M)
Operating Margin-5.4%13.1%-332.3%-112.8%-3099.9%
Interest Income004.96M7.39M6.58M
Interest Expense2.84M3.03M2.83M00
Other Income / Expenses(5.12M)20.23M(152.29M)(33.24M)(52.79M)
Income Before Tax(9.72M)34.77M(238.71M)(77.14M)(139.5M)
Pre-Tax Margin-11.4%31.4%-918.0%-198.2%-4987.3%
Income Tax Expense15.97M(609K)(19M)287K(9.19M)
Net Income(25.69M)35.38M(219.71M)(77.42M)(130.3M)
Net Margin-30.2%31.9%-844.9%-199.0%-4658.6%
EPS (Basic)(6.74)7.33(49.76)(2.99)(5.02)
EPS (Diluted)(6.60)3.00(49.76)(3.29)(5.02)
Weighted Avg Shares3.18M4.02M5.17M25.91M25.97M
Weighted Avg Shares (Diluted)3.18M4.05M5.17M23.69M25.97M

Cartesian Therapeutics, Inc.

NASDAQ:RNAC

Intrinsic Alpha fair value

Locked

Current Price

$6.30

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.